Literature DB >> 1606722

Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.

M F Prummel1, W M Wiersinga, R Van der Gaag, M P Mourits, L Koornneef.   

Abstract

In various autoimmune diseases circulating levels of soluble IL-2 receptor (sIL-2R) seem to be related to disease activity. Because reliable parameters of disease activity in Graves' ophthalmopathy are lacking, we measured sIL-2R levels in 47 patients with this disorder. The patients had Graves' disease, but no other immune-mediated diseases, had not yet received specific treatment for their ophthalmopathy and were euthyroid during the entire study period. Twenty-one of the 47 patients (45%) had sIL-2R values above the upper normal limit of 650 U/ml, as established in 20 healthy controls. There were no differences between patients with normal (median 469, range 280-644 U/ml) and elevated (median 946, range 678-1588 U/ml) sIL-2R levels regarding duration or severity of the eye disease (as assessed clinically from the total eye score). However, patients with severely enlarged eye muscles had higher sIL-2R values than patients with less severely enlarged eye muscles on CT scan. Patients with elevated sIL-2R tended to have a higher response rate (71%) to a 3-month course of prednisone, than those with normal levels (46%; P = 0.081). Since a successful outcome of prednisone treatment might be representative for disease activity, the elevated sIL-2R levels seem to reflect active inflammation. Although the practical relevance of this finding in individual patients is limited, it underscores the importance of cell-mediated immune responses in this thyroid-related eye disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606722      PMCID: PMC1554494          DOI: 10.1111/j.1365-2249.1992.tb06462.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy.

Authors:  C C Chow; K N Lai; J C Leung; J C Chan; C S Cockram
Journal:  Clin Endocrinol (Oxf)       Date:  1990-09       Impact factor: 3.478

Review 2.  Thyroid-associated eye disease: pathophysiology.

Authors:  A P Weetman
Journal:  Lancet       Date:  1991-07-06       Impact factor: 79.321

Review 3.  Management of dysthyroid eye disease.

Authors:  P Fells
Journal:  Br J Ophthalmol       Date:  1991-04       Impact factor: 4.638

4.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

5.  An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro.

Authors:  D L Nelson; L A Rubin; C C Kurman; M E Fritz; B Boutin
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

Review 6.  Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment.

Authors:  D H Jacobson; C A Gorman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

7.  The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals.

Authors:  R Wilson; J H McKillop; L M Buchanan; H Bradley; W E Smith; J A Thomson
Journal:  Autoimmunity       Date:  1990       Impact factor: 2.815

8.  Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription.

Authors:  D T Boumpas; E D Anastassiou; S A Older; G C Tsokos; D L Nelson; J E Balow
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

9.  Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.

Authors:  M F Prummel; M P Mourits; A Berghout; E P Krenning; R van der Gaag; L Koornneef; W M Wiersinga
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

10.  High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.

Authors:  E Koukkou; P Panayiotidis; V Alevizou-Terzaki; N Thalassinos
Journal:  J Clin Endocrinol Metab       Date:  1991-10       Impact factor: 5.958

View more
  8 in total

1.  Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.

Authors:  I M Wakelkamp; M N Gerding; J W Van Der Meer; M F Prummel; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 2.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

3.  Serum levels of interleukin-12 in Graves' disease and their dynamic changes after surgery.

Authors:  Saburo Murakami; Katsuhiko Okubo; Yoshitaka Tsuji; Hideto Sakata; Masataka Kikuchi; Takehiro Takahashi; Takaharu Kato; Renzo Hirayama
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

4.  Serum-soluble interleukin-2 receptor levels before and after surgical treatment for Graves' disease.

Authors:  S Murakami; A Kobayashi; K Kuma; H Murai; Y Okamura; A Satomi; K Ishida
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 5.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

6.  T cell responses to orbital antigens in thyroid-associated ophthalmopathy.

Authors:  K Arnold; N Tandon; R S McIntosh; R Elisei; M Ludgate; A P Weetman
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

7.  The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases.

Authors:  J Jiskra; M Antosová; Z Límanová; Z Telicka; Z Lacinová
Journal:  Clin Exp Immunol       Date:  2009-02-04       Impact factor: 4.330

8.  Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy.

Authors:  Edina Kishazi; Marianne Dor; Simone Eperon; Aurélie Oberic; Natacha Turck; Mehrad Hamedani
Journal:  Sci Rep       Date:  2018-07-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.